CVS Caremark Corp. reported a drop in third-quarter profit as its pharmacy benefit unit continued losing business from previously canceled contracts.
Biotechnology company Biogen Idec Inc. said it is laying off 13 percent of its work force, or 650 employees, in a restructuring and cost-cutting move. Weston, Mass. based Biogen will have 4,275 employees after the cuts.
Gilead Sciences, Inc. announced data from a Phase 2a study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus.
Cell Therapeutics, Inc. announced that it has submitted a marketing authorization application to the European Medicines Agency for Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Discovery Laboratories, Inc. announced that the Food and Drug Administration has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis.
NuPathe Inc. announced that the company submitted a New Drug Application for Zelrix to the U.S. Food and Drug Administration. Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.
XOMA Ltd announced several presentations that will highlight advances in the company's biodefense program and particularly in the development of XOMA 3AB, an antibody co-mixture that binds to distinct regions of botulinum toxin type A.
Hyperion Therapeutics, Inc. announced that the company’s phase 3 pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders, met its primary endpoint.
The investigated drug trabedersen (AP 12009) is a gene silencing antisense compound – a phosphorothioate oligodeoxynucleotide – designed to selectively downregulate the production of transforming growth factor-beta 2 (TGF-?2) at the translational level.
Photometrics, a designer and manufacturer of high-performance CCD and EMCCD cameras for the life sciences, has exclusively integrated eXcelon sensor technology in its Evolve 512 and 128 EMCCD cameras.
NanoString Technologies, Inc. announced the launch of a novel solution for detecting genetic copy number variations associated with disease susceptibility, drug response, and cancer progression.
Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.
RecipharmCobra Biologics, an international manufacturer of biopharmaceuticals, announces that the French Ministry for Higher Education and Research has recognised RecipharmCobra as an approved research and development service provider.
Rather than a “one-size-fits-all” treatment plan, researchers say lung cancer patients should receive care based on their specific diagnosis, individual genetic makeup and particular tumors.
Omega-3 pills promoted as boosting memory didn't slow mental and physical decline in older patients with Alzheimer's disease, a big disappointment in a multimillion-dollar government-funded study.